Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Isis Pharmaceuticals begins phase II study of ISIS-FXIRx in end-stage renal disease

Nov. 3, 2015

Taiho starts phase I trial of TAS-303 in women with stress urinary incontinence

Nov. 3, 2015

Revive Therapeutics' bucillamine receives orphan drug designation for cystinuria

Oct. 30, 2015

Researchers devise mouse model of nocturnal polyuria

Oct. 26, 2015

AF-219 improves symptoms in patients with interstitial cystitis/bladder pain syndrome

Oct. 26, 2015

Cinryze receives FDA fast track designation

Oct. 14, 2015

Astellas Pharma describes prostanoid EP4 antagonists

Oct. 14, 2015

New financing round at Pharmalink to fund development of phase III program for Nefecon

Oct. 6, 2015

Fexeric approved in Europe for hyperphosphatemia in patients with chronic kidney disease

Sep. 25, 2015

NecroX-7 reduces renal ischemia-reperfusion injury in vivo

Sep. 17, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...